Abstract. CD40 ligand (CD40L) gene therapy offers a potentially useful option for lung cancer due to its multiple antitumor activities. However, membrane-bound CD40L may be proteolytically cleaved to form soluble CD40L (sCD40L), which results in adverse effects. In a previous study by our group, it was demonstrated that recombinant self-complementary adeno-associated virus 5 (scAAV5) efficiently delivered genes to lung cancer cells. In the present study, an scAAV5 expressing a non-cleavable human CD40L mutant (scAAV5-CD40L-M) was generated and its direct antitumor effects in lung cancer were evaluated. Transduction with scAAV5-CD40L-M resulted in effective expression of CD40L on the cell surface with low levels of cleaved sCD40L, which significantly reduced the percentage of viable cells and promoted caspase-3-dependent apoptosis of CD40-positive lung carcinoma A549 cells, compared with scAAV5-CD40L transduction (P<0.05). Furthermore, treatment with scAAV5-CD40L-M exerted a significant antitumor effect against CD40-positive A549 xenografts by inducing apoptosis (P<0.05) with few side effects. Gene therapy using an scAAV5 vector expressing non-cleavable human CD40L mutant may therefore have direct antitumor effects against CD40-positive lung cancers. These tumoricidal effects of scAAV5-CD40L-M treatment make it a promising therapeutic technique for the treatment of lung cancer.
Introduction
Lung cancer is a leading cause of global cancer-associated mortality (1) . Non-small cell lung cancer (NSCLC) accounts for ~80% of all types of lung cancer. Although recent advances have been made in the development of diagnosis and treatment strategies, the prognosis of patients with NSCLC remains poor (2) .
Immunogene therapy using immunostimulatory molecules to enhance anti-tumor immunity offers a promising therapeutic option for lung cancer (3) . The CD40 ligand (CD40L), a type Ⅱ membrane-bound protein belonging to the tumor necrosis factor (TNF) superfamily, was used in cancer gene therapy due to its ability to trigger Th1-type immune responses that drive effector cells, including cytotoxic T lymphocytes, natural killer cells and M1 macrophages, which normalize the tumor microenvironment and directly suppress the growth of certain CD40-positive tumors (4) . Novel therapies based on CD40L, including infusion of recombinant CD40L protein, anti-CD40 antibodies and CD40L gene therapy, potentially provide numerous anti-cancer approaches in one therapy and offer an attractive option for clinical trials (5) (6) (7) .
Several studies indicated that the precise form of the CD40 stimulus, inducing a membrane-bound and soluble version of CD40L (sCD40L), influenced the therapeutic responses in carcinoma cells. sCD40L is shed from membrane-bound forms via matrix metalloproteinase (MMP) cleavage and provides local cytokine-like amplification of CD40 signaling (8) . A study indicated that sCD40L induced pro-survival and pro-apoptotic signals in CD40-positive solid carcinoma cells (9) . In clinical trials, elevated serum levels of sCD40L were found in autoimmune diseases, metabolic and cardiovascular diseases and the cytokine-like effects of sCD40L may contribute to the pathogenesis of these disorders by acting on CD40(+) bystander cells (10, 11) . Membrane-bound CD40L, however, through sustained activation of TNF receptor-associated factor 3 (TRAF3)-dependent c-Jun N-terminal kinase signals and suppression of TRAF6-dependent survival signals, was able to directly induce cell death whilst creating few side effects (12) . Therefore, as a potential anti-cancer therapeutic, membrane-bound CD40L presents a more attractive option than its soluble form.
To circumvent the possible stimulating proliferative activity and adverse inflammatory effects caused by sCD40L, a membrane-stable mutant form of human CD40L (CD40L-M) was designed and engineered. As a means of delivering CD40L-M for clinical application, the transduction efficiency of various serotypes of adeno-associated virus (AAV) vectors in an NSCLC cell line were examined. The efficient recombinant self-complementary AAV5 (scAAV5) was subsequently selected as a therapeutic vehicle (11) . An scAAV5 encoding human CD40L mutant (AAV5-CD40L-M), which results in consistent expression of ligand at the cell membrane, was generated. The direct anti-tumor effects of cleavage-resistant CD40L delivered by scAAV5 were examined in vitro and in vivo.
Materials and methods
Cell culture. The human NSCLC cell lines A549 and H1650 and the human embryonic kidney cell line HEK293 (293T) were obtained from the Cell Resource Center (Shanghai, China). The cells were maintained in RPMI-1640 medium (Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Gibco-BRL, Grand Island, NY, USA).
Construction of scAAV5 vectors. Plasmids pdsAAV-CB-CD40L
and pdsAAV-CB-CD40L-M, which are self-complementary double-sequence AAV plasmids containing human wild-type CD40L cDNA and CD40L-M cDNA (containing six substitutions: Gln114 to Pro114, Lys115 to Arg115, Asp117 to Glu117, Gln118 to Glu118, Asn119 to Asp119 and Pro120 to Ser120), were constructed by Invitrogen Life Technologies (Carlsbad, CA, USA) (13, 14) . AAV vectors were generated as described by the Penn Vector Core (http://www.med.upenn. edu/gtp/vector_core/production.shtml). Briefly, a plasmid encoding the transgene of interest, expressed from a cytomegalovirus enhancer/β-actin (CB) promoter, flanked by AAV2 inverted terminal repeats, was packaged by triple transfection of HEK293 cells with plasmids encoding the AAV2 rep gene and the AAV5 cap gene and an adenovirus helper plasmid (Fig. 1A ). Vectors were purified by CsCl ultracentrifugation and titers were determined by slot blot analysis, as previouslt described (15) .
Quantitative polymerase chain reaction (qPCR)
. PCR was performed using the SYBR Green RT-PCR kit (Toyobo Co., Ltd., Osaka, Japan) according to the manufacturer's instructions. The PCR primer pairs used were as follows: CD40L (NM-000074, position 488-620, 132 bp fragment) forward, 5'-TGA GCA ACA ACT TGG TAA CCC TGG-3' and reverse, 5'-CTG GCT ATA AAT GGA GCT TGA CTC G-3'; β-actin (NM-001101, position 939-1124, 205 bp fragment) forward, 5'-TGA CGT GGA CAT CCG CAA AG-3' and reverse, 5'-CTG GAA GGT GGA CAG CGA GG-3' (Invitrogen Life Technologies).
Flow cytometric analysis. CD40L and CD40 expression was determined by flow cytometry (FACSCalibur; BD Biosciences, Franklin Lakes, NJ, USA) using an allophycocyanin (APC)-conjugated CD154 antibody (Ab) diluted at 1:25 or phycoerythrin (PE)-conjugated CD40 Ab diluted at 1:50. Appropriate APC-or PE-conjugated isotype control was used to measure background staining. Annexin V-fluorescein isothiocyanate (FITC) and/or propidium iodide (PI) staining (TACS Annexin V-FITC kit; Trevigen, Gaithersburg, MD, USA) was used to detect apoptotic cells. Caspase-3 inhibitor (Ac-DEVD-CHO; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) was employed in a competition experiment.
Cell viability assay. Cell viability was determined by MTT assay using a Cell Proliferation Kit I (Roche Diagnostics GmbH, Mannheim, Germany). Cancer cells were seeded into 96-well plates. After incubation, the medium was replaced with 50 µl MTT reagent (2 mg/ml) followed by further incubation in an incubator for 2 h. Next, the medium was removed and dimethylsulfoxide (150 µl) was added to each well. The absorbance at 560 nm was measured with a spectrophotometer (PerkinElmer, Waltham, MA, USA). A competition experiment with anti-human CD40L monoclonal antibody (100 ng/l; BioLegend, Inc., San Diego, CA, USA) was performed.
Western blot analysis. Briefly, proteins were separated by 6-15% SDS-PAGE and transferred to polyvinylidene difluoride membranes (Hybond-P; GE Healthcare, Little Chalfont, UK). The primary antibodies used were: Rabbit anti-caspase-3 polyclonal antibody (pAb; 1:100; sc-7148) and rabbit anti-β-actin pAb (1:1,000; sc-130656; Santa Cruz Biotechnology, Inc.). The secondary antibodies were horseradish peroxidase-conjugated antibodies against rabbit immunoglobulin G (GE Healthcare, Waukesha, WI, USA). Immunoreactive bands in the western blots were visualized using enhanced chemiluminescence substrates (ECL Plus; GE Healthcare).
Caspase-3 activity assay. The activity of caspase-3 was evaluated using the Caspase-3 Activity Assay kit (C115; Beyotime Institute of Biotechnology, Haimen, China) according to the manufacturer's instructions. The caspase-3 activity assay is based on spectrophotometric detection of the chromophore p-nitronanilide (pNA), following its cleavage from the labeled substrate. The release of pNA was quantified by determining the absorbance using a Sunrise™ microplate reader (Tecan Group, Ltd., Männedorf, Switzerland) at 405 nm.
ELISA. The concentration of sCD40L in supernatants and serum following treatment were measured using a human sCD40L ELISA kit (ELH-CD40L-001; RayBiotech, Inc., Norcross, GA, USA) according to the manufacturer's instructions.
Mouse model studies. Xenografts were prepared by implanting tumor fragments derived from A549 cells [5x10 6 cells suspended in 100 µl phosphate-buffered saline (PBS)] subcutaneously into the back of six-week-old male BALB/c nude mice. The mice were obtained from the animal center at Nanjing Medical University (Nanjing, China). All mice were maintained on a diet of standard rodent chow and water supplied ad libitum, with a regular light-dark cycle and at 23˚C. When the tumor volume reached ~100 mm 3 , the mice were randomly divided into four groups (six mice/group). Intratumoral injection with 0.5 ml scAAV5-GFP, scAAV5-CD40L and scAAV5-CD40L-M vectors, respectively, [at 1x1,011 viral genomes (vgs)/mouse] or 0.5 ml PBS was performed.. Tumor growth was subsequently monitored every three days for 30 days by measuring tumor size with a caliper. The tumor volume was calculated using the following formula: Tumor volume = length x width 2 x 0.5. All animal experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Committee on the Ethics of Animal Experiments of Nanjing Medical University (permit number, 307005).
Immunohistochemistry. Immunohistochemistry using the rabbit anti-CD40L antibody (ab65854; Abcam, Cambridge, UK) was employed to investigate paraffin wax-embedded tissue sections using a routine avidin-biotin-immunoperoxidase technique (Histostain-Plus kit, Zymed, San Franzisco, USA). For quantitative analysis of apoptosis, sections were assayed by the terminal deoxynucleotidyl transferase-mediated dUTP-FITC nick end-labeling (TUNEL) method using a One
Step TUNEL Apoptosis Assay kit (C1086; Beyotime). The number of positive cells was counted in ten random fields using microscopy (magnification, x100; LSM 700; Carl Zeiss, Oberkochen, Germany). 
Results
Expression of scA AV5-CD40L -M. The expression cassette containing the CD40L or CD40L-M cDNA was inserted into the cloning site of pdsAAV-CB-GFP to create the expression plasmid pdsAAV-CB-CD40L or pdsAAV-CB-CD40L-M, respectively. The correct plasmids were identified by sequencing. Recombinant scAAV5-CD40L and scAAV5-CD40L-M vectors (Fig. 1A) were generated as aforementioned. These viruses were used to infect the A549, H1650 and 293T cell lines. Expression of CD40 was detected in the A549 cell line (65.63±6.02%), but not in the H1650 or 293T cell lines. Infection with the equivalent multiplicity of infection (MOI, 10 4 vgs/cell) of CD40L-M resulted in membranous ligand expression determined by flow cytometry (Fig. 1B) . Expression of CD40L and CD40L-M was confirmed by qPCR analysis (Fig. 1C) .
s cA AV5 -CD 4 0 L -M i n h ibits th e prolifera t io n of CD40-positive cell lines. The direct growth-inhibitory activities of scAAV5-CD40L and scAAV5-CD40L-M were assessed by MTT assay using CD40-positive A549 and CD40-negative H1650 lung cancer cell lines. Significantly decreased A549 viability was observed ( Fig. 2A) scAAV5-CD40L-M, 18.92±2.03%; versus scAAV5-green fluorescent protein (GFP); P<0.01). A significant difference between the viability of scAAV5-CD40L/A549 cells and that of scAAV5-CD40L-M/A549 cells was also distinguishable (P<0.05). This inhibitory effect was attenuated when cells were pre-incubated with an anti-CD40L monoclonal antibody. By contrast, no difference was observed in the CD40-negative H1650 cells following transduction (Fig. 2B) . 
scAAV5-CD40L-M induces CD40-positive A549 cell apoptosis.
Relative to CD40-negative H1650 cells, scAAV5-CD40L and scAAV5-CD40L-M (10 4 vgs/cell) were found to induce CD40-positive A549 cell apoptosis as indicated by Annexin V-FITC/PI double staining with apoptotic rates of 17.83±1.32 and 12.56±1.05%, indicating a significant difference between the two groups (P<0.05; Fig. 3A) .
To investigate whether the apoptotic effect observed was associated with caspase-3 activation, western blot analysis was used to examine the expression levels of cleaved caspase-3 in A549 cells. The expression levels of cleaved caspase-3 protein in scAAV5-CD40L-M-infected cells were higher than those in scAAV5-CD40L-infected cells (10 4 vgs/cell; Fig. 3B ). Caspase-3 activity was further analyzed by enzymatic assay. The level of caspase-3 activation was markedly higher in cells transduced with scAAV5-CD40L-M for 48 h than that of cells exposed to scAAV5-CD40L or AAV5-GFP (Fig. 3C) . Apoptosis was not induced when the cells were pre-incubated with caspase-3 inhibitor (data not shown). These results indicated that CD40L-associated cell death may be mediated by a caspase-dependent signaling pathway.
s CD4 0L secretion is signif ica ntly decreased in scAAV5-CD40L-M-transduced cells. Secretion of sCD40L
following transduction was detected in supernatants to examine whether CD40L-M was resistant to cleavage on the cell surface. As indicated in Fig. 4A and B, the amount of sCD40L from the culture supernatants of scAAV5-CD40L-transduced cells was significantly increased following transduction compared with that of the corresponding mock and CD40L-M groups (P<0.01).
Antitumor activity of scAAV5-CD40L-M against lung cancer xenografts. To focus on the direct tumor growth-inhibitory features of AAV5-CD40L-M, in vivo analyses were performed via lung cancer heterotransplants in athymic nude mice. scAAV5-CD40L and scAAV5-CD40L-M each effectively decreased the tumor growth rate (Fig. 5A) . The mean tumor weights were 0.43±0.03, 0.31±0.02 and 0.29±0.03 g in the scAAV5-GFP, scAAV5-CD40L and scAAV5-CD40L-M groups, respectively (Fig. 5B) .
C D 4 0 L e x p r e s s i o n w a s d e t e c t e d i n t h e scAAV5-CD40L-and scAAV5-CD40L-M-injected tumors but not in the scAAV5-GFP-injected tumors (Fig. 5C ). The effect of scAAV5-CD40L-M treatment on apoptosis was assessed using an in situ TUNEL assay. The most significant level of apoptosis was observed in the tumors of mice receiving scAAV5-CD40L-or scAAV5-CD40L-M-treatment, compared with that of scAAV5-GFP mice ( Fig. 5D; P<0 .05, respectively).
The systemic toxicity of scAAV5-CD40L-M treatment was examined. Histopathological studies indicated no apparent lesions in the lung, liver, spleen or kidney. Levels of sCD40L in serial serum samples were ~0. Serum alanine transaminase, aspartate aminotransferase, serum urea nitrogen and creatinine were determined. No significant difference was detected between groups (Data not shown).
Discussion
CD40L transgene expression in human CD40-positive solid carcinoma cells was found to produce a direct growth-inhibitory effect through apoptotic induction and/or cell cycle blockage (16) (17) (18) (19) (20) (21) (22) . However, sCD40L cleaved from membrane-bound CD40L may regulate CD40L activity by downregulating surface CD40L and quenching CD40L with an sCD40L 'decoy' (23), which is unable to induce survival signals in cancer cells (24) or enter into the systemic circulatory system and cause inflammatory diseases (10, 11) . Therefore, in the present study, to reduce the adverse effects caused by sCD40L, a human CD40L mutant that was resistant to proteolytic cleavage was generated as a candidate gene for immunogenetic therapy of lung cancer.
Successful gene therapy is dependent upon the efficiency and availability of gene delivery systems. Recombinant AAVs have been widely used for gene delivery in animal models and their use in human gene therapy is currently being evaluated in clinical trials (http://www.abedia.com/wiley/). However, limitations in vector tropism, including limited tissue specificity and insufficient transduction efficiencies, preclude therapeutic applications in certain tissues (25) . To achieve greater efficacy of AAV-gene therapy for lung carcinoma, the transduction efficiency of various AAV vector serotypes in NSCLC cell lines were examined. The results demonstrated that scAAV5 vectors, which bypass the requirement of conventional viral second-strand DNA synthesis, are the most robust to deliver the gene in A549 cells (13) . Recently, a study verified that N-linked sialic acid on the surface of lung cancer cells mediates tropism of vectors based on AAV5 (26) . Therefore, based on previous studies, a recombinant scAAV5 expressing mutant CD40L was generated in the present study to further explore the direct antitumor effects of wild-type and cleavage-resistant CD40L in vitro and in vivo.
The results of the present study indicated that scAAV5-CD40L-M produced a more profound growth-inhibitory effect in CD40-positive cells compared with that in wild-type scAAV5-CD40L. Caspase-3 activation assay and Annexin V staining confirmed that CD40L-M was a more potent inducer of apoptosis than the wild-type CD40L, which was in agreement with previous studies by Elmetwali et al (12) and Vardouli et al (17) . It is possible that this augmented antitumor activity was a result of 'suicide' and 'fratricide' through constitutive stimulation of CD40 signals by CD40L expression. This antitumor activity was further confirmed in vivo by treatment of pre-existing A549 xenografts without detectable side effects.
In conclusion, the results of the present study demonstrated the direct antitumor effects of scAAV5 delivery of membrane-stable mutant CD40L on human CD40-positive lung carcinomas in vitro and in vivo with few side effects. The balance between the direct cancer growth inhibition of scAAV-CD40L-M with its immune-activating properties will be examined in forthcoming studies, using a murine, immunocompetent syngeneic cancer model. Research Project of Jiangsu Province (Nanjing, China; no. 12KJB320004).
